

1 MAR 2004

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number
WO 01/17984 A1

(51) International Patent Classification⁷: C07D 311/18,
405/06, 409/06, A61K 31/37, A61P 35/00

(21) International Application Number: PCT/EP00/08367

(22) International Filing Date: 28 August 2000 (28.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9920908.2 3 September 1999 (03.09.1999) GB

(71) Applicant (for all designated States except US): INDENA
S.P.A. [IT/IT]; Viale Ortles, 12, I-20139 Milan (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BOMBARDELLI,
Ezio [IT/IT]; Via Val di Sole, 22, I-20141 Milano (IT).
VALENTI, Piero [IT/IT]; Viale Lenin, 55, I-40139
Bologna (IT).

(74) Agents: RITTER, Stephen, David et al.; Mathys &
Squire, 100 Gray's Inn Road, London WC1X 8AL (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: CHALCONE COUMARINS



(I)

(57) Abstract: Disclosed are novel chalcone derivatives having Formula (I). The compounds possess antiproliferative activity, and are useful for the manufacture of a medicament for the treatment or prevention of neoplasms, particularly those located in the uterus, ovary or breast. The compounds of the invention may also be useful in the manufacture of a medicament for the treatment or prevention of menopausal disorders and osteoporosis.

WO 01/17984 A1

2002 00523-9

CHALCONE COUMARINS

The present invention relates to a novel class of compounds which have structures related to certain naturally occurring and synthetic chalcones, as well as to methods for the preparation of such compounds and to pharmaceutical uses thereof.

The compound 1,3-diphenyl-2-propene-1-one is known by the trivial name chalcone. Many naturally occurring flavonoids share structural features with chalcone and are referred to by the generic term "chalcones". Also, certain flavonoids, including ones which are also classified as chalcones, have recently been demonstrated to have anticancer activity (Cancer Research 48, 5754, 1988) and chemopreventive activity in some tumours (J. Nat. Prod. 53, 23, 1990).

In particular, quercetin, an ubiquitous flavonoid found in plants, has been shown to act on the proliferation of human leukemic cells (Br. J. of Haematology, 75, 489, 1990) and on other cell lines (Br. J. Cancer 62 94, 942, 1990; Int. J. Cancer, 46, 112, 1990; Gynaecologic Oncology, 45, 13, 1992) and to possess a synergic action with common antiproliferative drugs.

In addition, some natural or synthetic chalcones, described in our International Patent Publication No. WO 9117749 and in International Patent Publication No. WO 96/19209 (Baylor College of Medicine) have proved to have a significant antiproliferation activity on a variety of different cell lines.

Although the mechanism of action of the antiproliferative activity of flavonoids and chalcones is still unknown, it is believed to be linked to the interaction of these compounds with type II estrogen receptors.


The action *in vivo* of these polyphenol substances is certainly much more complicated. All these compounds are generally characterised by an almost

-2-

complete insolubility in water and, *in vivo*, by a very poor bioavailability linked to a rapid metabolism of phenols and a marked affinity for lipids and proteins.

Surprisingly, it has now been found that certain novel chalcones, chalcone derivatives and chalcone analogues, in particular ones in which the phenyl ring in the 1-position is substituted or replaced by rings containing one or more heteroatoms, possess a greater antiproliferation activity both on sensitive cancerous cells and on cells which are resistant to common chemotherapeutic drugs, including the latest generation anti-neoplastic agents, paclitaxel and docetaxel.

Thus according to one aspect of the present invention, there are provided compounds of the general Formula (I):



or a pharmaceutically acceptable salt or solvate thereof wherein:

Ar represents:

a substituted or unsubstituted, (preferably aromatic), carbocyclic or heterocyclic group, said carbocyclic or heterocyclic group containing from 5 to 10 ring atoms, said ring atoms forming one or two rings, wherein the or each ring contains 5 or 6 ring atoms, any heteroatoms being selected from N, O and S, any substituents on the Ar group being independently selected from the group consisting of:

- (a) Cl, (b) Br, (c) F, (d) OH, (e) NO₂, (f) CF₃, (g) C₁₋₄ lower alkyl (in particular CH₃), (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁸) wherein R⁶ and R⁸ are the same or different and each represents H or lower C₁₋₄ alkyl,

-3-

(k) OR^{10} wherein R^{10} represents a saturated or unsaturated lower C_{1-6} straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from:

Cl, Br, F, OMe, NO_2 and CF_3 ,

and (l) $-OCOR^{11}$, wherein R^{11} represents a saturated or unsaturated lower C_{1-6} straight or branched hydrocarbyl group or a phenyl group;

R represents

OH, OR^{10} or $OCOR^{11}$, wherein R^{10} and R^{11} are as defined above; and

R^1 represents H or a lower C_{1-6} straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from Cl, Br, F, OMe, NO_2 and CF_3

with the proviso that:

- (1) when $R^1 = CH_3$ and $R = OH$:
the group Ar cannot be: 3-pyridyl, 4-pyridyl, 4-methylphenyl, 3-nitrophenyl, 3-methoxy-4-ethoxyphenyl, 3-methoxy-4-n-butoxyphenyl, 4-(N,N-dimethylamino)phenyl, 2-hydroxy-3,5-dibromophenyl, 2-hydroxy-5-methylphenyl, 4-chlorophenyl, phenyl, 3-methoxyphenyl, 4-methoxyphenyl, or 3,4-dimethoxyphenyl;
- (2) when $R^1 = CH_3$ and $R = OCOCH_3$:
the group Ar cannot be: phenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 4-(N,N-dimethylamino)phenyl, 3-methoxy-4-acetoxyphenyl, 3,4,5-trimethoxyphenyl, 2-chlorophenyl, or 3,4-methylenedioxyphenyl;
- (3) when $R^1 = H$ and $R = OCH_3$ or OH, the group Ar cannot be 4-methoxyphenyl; and
- (4) when $R^1 = CH_3$ and $R = OCH_3$ or OH, the group Ar cannot be 4-methoxyphenyl or 3,4-dimethoxyphenyl.

-3A-

A preferred class of compounds of Formula (I) are those wherein Ar represents a substituted or unsubstituted (preferably aromatic), heterocyclic group said heterocyclic group containing from 5 to 10 ring atoms, said ring atoms forming one or two rings, wherein the or each ring contains 5 or 6 ring atoms, the heteroatoms being selected from N, O and S, and any substituents on the Ar group being independently selected from the group consisting of:

(a) Cl, (b) Br, (c) F, (d) OH, (e) NO₂, (f) CF₃, (g) C₁₋₄ lower alkyl (in particular CH₃), (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁸) wherein R⁶ and R⁸ are the same or different and each represents H or lower C₁₋₄ alkyl (preferably R⁶ and R⁸ are the same or different and each represents H or lower C₁₋₄ alkyl), (k) OR¹⁰ wherein R¹⁰ represents a saturated or unsaturated lower C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from:

Cl, Br, F, OMe, NO₂ and CF₃,

and (l) -OCOR¹¹, wherein R¹¹ represents a saturated or unsaturated lower C₁₋₆ straight or branched hydrocarbyl group or a phenyl group.

In a preferred class of compounds, Ar contains a basic nitrogen function, for example,

by virtue of a heterocyclic nitrogen ring atom being present, or Ar may contain a substituent having a basic nitrogen, such as an amine, or an acetamido function. Thus accordingly, the Ar group is preferably a substituted or unsubstituted (preferably aromatic), heterocyclic group, said heterocyclic group containing from 5 to 10 ring atoms, wherein at least one of the ring atoms is a nitrogen atom and any substituent on the ring is as defined as for Formula (I). Particularly preferred Ar groups include pyridyl or indolyl.

A second preferred group of compounds of Formula (I) are those wherein Ar represents a substituted or unsubstituted (preferably aromatic), carbocyclic group, said carbocyclic group containing from 5 to 10 ring atoms, said ring atoms forming one or two rings, wherein the or each ring contains 5 or 6 ring atoms, and any substituents on the Ar group being independently selected from the group consisting of:

(a) Cl, (b) Br, (c) F, (d) OH, (e) NO₂, (f) CF₃, (g) C₁₋₄ lower alkyl (in particular CH₃), (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁸) wherein R⁶ and R⁸ are the same or different and each represents H or lower C₁₋₄ alkyl, (k) OR¹⁰ wherein R¹⁰ represents a saturated or unsaturated lower C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from:

Cl, Br, F, OMe, NO₂ and CF₃,

and (l) -OCOR¹¹, wherein R¹¹ represents a saturated or unsaturated lower C₁₋₆ straight or branched hydrocarbyl group or a phenyl group.

For the compounds of Formula (I), any substituents on the Ar group are preferably selected from the group consisting of: NHCOCH₃, N(R⁶)(R⁸), OR¹⁰ and -OCOR¹¹, wherein R⁶, R⁸, R¹⁰ and R¹¹ are as defined as above for Formula (I). R¹⁰ and R¹¹ preferably represent a saturated or unsaturated C₁₋₆ straight chain or branched hydrocarbyl group, in particular methyl, ethyl, n-propyl or isopropyl.

Of this preferred class, Ar is preferably substituted with one or more OR¹⁰ groups,

wherein R^{10} represents a saturated or unsaturated lower C_{1-6} straight or branched hydrocarbyl group. An especially preferred R^{10} group is methyl. Particularly preferred Ar groups include phenyl or phenyl substituted with 1, 2 or 3 methoxy groups.

5 For the preferred class of compounds wherein Ar comprises at least one basic nitrogen function, and wherein Ar represents a carbocyclic ring, the basic nitrogen function is provided by virtue of the carbocyclic ring comprising at least one substituent selected from $NHCOCH_3$ or $N(R^6)(R^8)$, wherein R^6 and R^8 are as defined as for Formula (I).

10 For the compounds of Formula (I), R preferably represents an unsaturated lower C_{1-6} straight or branched hydrocarbyl group. In particular, R represents $OCH=C(CH_3)_2$, $OCH_2CMe=CH_2$, $OCH_2CH=CH_2$ or $OCH_2C\equiv CH$. An especially preferred group of compounds are those wherein Ar is selected from phenyl, trimethoxyphenyl, 3-pyridyl, 4-pyridyl or 3-indolyl and R is selected from $OCH=C(CH_3)_2$, $OCH_2CMe=CH_2$,
15 $OCH_2CH=CH_2$ or $OCH_2C\equiv CH$.

For the compounds of Formula (I), R^1 preferably represents a lower C_{1-6} straight or branched hydrocarbyl group, especially methyl.

20 A further group of preferred compounds of Formula (I) include those wherein:
Ar represents

phenyl, which may be unsubstituted or substituted by one, two or three substituents independently selected from

25 Cl, Br, F, OMe, NO_2 , CF_3 , C_{1-4} lower alkyl (in particular CH_3), NMe_2 , NEt_2 ,
 SCH_3 and $NHCOCH_3$;


thienyl, 2-furyl, 3-pyridyl, 4-pyridyl or indolyl.

R represents

OH or OCH_2R^1 , wherein R^1 is selected from $-CH=CMe_2$, $-CMe=CH_2$, $-CH=CH_2$ and $-C\equiv CH$.

It will be appreciated that compounds of Formula (I) which contain a basic amino function may be converted to acid addition salts, with pharmacologically acceptable acids, e.g. hydrochloric acid and phosphoric acid. Such salts are also included in the present invention.

The present invention also provides the use of a compound of Formula (I):



or a pharmaceutically acceptable salt or solvate thereof wherein:

Ar represents:

a substituted or unsubstituted, (preferably aromatic), carbocyclic or heterocyclic group, said carbocyclic or heterocyclic group containing from 5 to 10 ring atoms, said ring atoms forming one or two rings, wherein the or each ring contains 5 or 6 ring atoms, any heteroatoms being selected from N, O and S, any substituents on the Ar group being independently selected from the group consisting of:

- (a) Cl, (b) Br, (c) F, (d) OH, (e) NO₂, (f) CF₃, (g) C₁₋₄ lower alkyl (in particular CH₃), (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁸) wherein R⁶ and R⁸ are the same or different and each represents H or lower C₁₋₄ alkyl,
- (k) OR¹⁰ wherein R¹⁰ represents a saturated or unsaturated lower C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from:

Cl, Br, F, OMe, NO₂ and CF₃,

and (l) -OCOR¹¹, wherein R¹¹ represents a saturated or unsaturated lower C₁₋₆ straight or branched hydrocarbyl group or a phenyl group;

R represents

-6A-

OH, OR¹⁰ or OCOR¹¹, wherein R¹⁰ and R¹¹ are as defined above; and R¹ represents H or a lower C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from Cl, Br, F, OMe, NO₂ and CF₃,

in the manufacture of an antiproliferative medicament. In particular, the compounds of the present invention may be useful for the manufacture of a medicament for the treatment or prevention of neoplasms, particularly those located in the uterus, ovary or breast. In particular, the compounds may be useful for the manufacture of a medicament for the treatment of cancer cells that are resistant to paclitaxel and docetaxel.

The compounds of Formula (I) may advantageously be used in combination therapies involving the combined use of a compound of Formula (I) and another anti-neoplastic agent, especially paclitaxel or docetaxel. The combination therapy may involve simultaneous or successive administration of a compound of Formula (I) and an anti-neoplastic agent. Such combination therapy forms a further aspect of the invention.


The compounds of the invention may be further used in the manufacture of a medicament for the treatment or prevention of menopausal disorders and osteoporosis.

The present invention further includes a pharmaceutical composition comprising one or more of the compounds of Formula (I) in combination with one or more pharmaceutically acceptable excipients.

The invention will now be described by way of illustrative examples and with reference to the accompanying formulae drawings.

EXAMPLES

Example 1. - General conditions to obtain chalcones.



5 **Method A.**

A solution of KOH 50% (3 ml) is added to an equimolar solution of a ketone (0.0075 mol) and an aldehyde (0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified. The precipitate is separated by filtration and dried under vacuum. The compounds are crystallized by ethanol or first separated by chromatography and then crystallized by ethanol.

10 **Method B.**

A solution of a ketone (0.0075 mol), an aldehyde (0.0075 mol), piperidine (15 ml) and acetic acid (75 ml) in ethyl alcohol 95% (80 ml) is countercurrent heated for 5 hours. Molecular sieves are added to the solution to eliminate water and the whole is left at rest for one night. The precipitate that is generally obtained is gathered and crystallized. If the product does not precipitate in these conditions, the solvent is vacuum evaporated and the residue is purified by chromatography on silica gel column.

Example 2. 1-[4-Methyl-7-(2-methylprop-1-enyloxy)coumarin-8-yl]-3-(pyridine-3-yl)-propen-1-one (see accompanying formula drawing VIB 106).

A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-(2-methylprop-1-enyloxy)-8-acetylcoumarin (2.14 g, 0.0075 mol) and pyridin-3-carboxaldehyde (0.8 g, 0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified. The precipitate is separated by filtration and dried under vacuum. The compound is crystallized by ethanol to give 0.84 g of product m.p. 156-157°C, ¹H-NMR (CDCl₃) δ: 1.69 (s, 3H); 1.72 (s, 3H); 2.44 (d, 3H, J = 1.22 Hz); 4.65 (d, 2H, J = 6.5 Hz); 5.34-5.38 (m, 1H); 6.16 (d, 1H, J = 1.2 Hz); 6.95 (d, 1H, J = 8.8 Hz); 7.07 (d, 1H, J = 18 Hz); 7.36 (d, 1H); 7.30-7.40 (m, 1H); 7.64 (d, 1H, J = 8.9 Hz); 7.90 (m, 1H); 8.58-8.68 (m, 2H).

Example 3. 1-[4-Methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl]-3-phenyl-propen-1-one (see accompanying formula drawing VIB 119).

A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-(3-methylbut-2-enyloxy)-8-acetylcoumarin (2.14 g, 0.0075 mol) and benzaldehyde (0.8 g, 0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified; the precipitate is separated by filtration and dried under vacuum. The compound is crystallized by ethanol to give 1.34 g of product m.p. 114-16°C, ¹H-NMR (CDCl₃) δ: 1.69 (s, 3H); 1.72 (s, 3H); 2.44 (d, 3H, J = 1.22 Hz); 4.65 (d, 2H, J = 6.5 Hz); 5.34-5.38 (m, 1H); 6.16 (d, 1H, J = 1.2 Hz); 6.95 (d, 1H, J = 8.8 Hz); 7.00 (d, 1H, J = 18 Hz); 7.10 (d, 1H); 7.30-7.40 (m, 3H); 7.45-7.52 (m, 12H); 7.61 (d, 1H, J = 8.9 Hz).

Example 4. 1-[4-Methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl]-3-(3,4,5-trimethoxyphenyl)propen-1-one (see accompanying formula drawing VIB 120).

A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-(3-methylbut-2-enyloxy)-8-acetylcoumarin (2.14 g, 0.0075 mol) and 3,4,5-trimethoxybenzaldehyde (1.47 g, 0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified. The precipitate is separated by filtration and dried under vacuum. The compound is crystallized by methanol to give 1.3 g of product m.p. 148-150°C, ¹H-NMR (CDCl₃) δ: 1.69 (s, 3H); 1.72 (s, 3H); 2.44 (d, 3H, J = 1.2 Hz); 3.74 - 3.88 (m, 9H); 4.65 (d, 2H, J = 6.5 Hz); 5.34-5.38 (m, 1H); 6.16 (s, 1H); 6.93 (d, 1H, J = 16 Hz); 6.95 (d, 1H, J = 8.9 Hz); 7.25 (d, 1H, J = 16 Hz); 7.63 (d, 1H, J = 8.9 Hz).

Example 5. 1-[4-Methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(pyridine-3-yl)-propen-1-one (see accompanying formula drawing VIB 122).

A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-methylallyloxy-8-acetylcoumarin (2.04 g, 0.0075 mol) and pyridin-3-carboxyaldehyde (0.8 g, 0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified. The precipitate is separated by filtration and dried under vacuum. The compound is crystallized by methanol to give 0.8 g of product m.p. 110-12°C, ¹H-NMR (CDCl₃) δ: 1.74 (s, 3H); 2.43 (s, 3H); 4.55 (s, 2H); 4.98 (d, 2H, J = 15 Hz); 6.16 (s, 1H); 6.93 (d, 1H, J = 8.9 Hz); 7.09 (d, 1H, J = 16 Hz); 7.35-7.37 (m, 1H); 7.36 (d, 1H, J = 16 Hz); 7.64 (d, 1H, J = 8.9 Hz); 7.85 (d, 1H, J = 7 Hz); 8.58 (d, 1H, J = 5 Hz); 8.67 (s, 1H).

Example 6. 1-[4-Methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-phenyl-propen-1-one
(see accompanying formula drawing VIB 121).

A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-methylallyloxy-8-acetylcoumarin (2.04 g, 0.0075 mol) and benzaldehyde (0.8 g, 0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified. The precipitate is separated by filtration and dried under vacuum. The compound is crystallized by methanol to give 1.2 g of product m.p. 158-160°C, ¹H-NMR (CDCl₃) δ: 1.74 (s, 3H); 2.43 (s, 3H); 4.55 (s, 2H); 4.98 (d, 2H, J = 15 Hz); 6.16 (s, 1H); 6.93 (d, 1H, J = 8.9 Hz); 7.02 (d, 1H, J = 16 Hz); 7.43-7.53 (m, 4H); 7.61 (d, 1H, J = 8.9 Hz).

Example 7. 1-[4-Methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(3-methoxy-phenyl)-propen-1-one
(see accompanying formula drawing VIB 162).

A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-methylallyloxy-8-acetylcoumarin (2.04 g, 0.0075 mol) and 3-methoxybenzaldehyde (1.01 g, 0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified. The precipitate is separated by filtration and dried under vacuum. The compound is crystallized by methanol to give 1.6 g of product m.p. 85-87°C, ¹H-NMR (CDCl₃) δ: 1.74 (s, 3H); 2.43 (s, 3H); 3.85-3.88 (m, 3H); 4.55 (s, 2H); 4.98 (d, 2H, J = 15 Hz); 6.16 (s, 1H); 6.93 (d, 1H, J = 8.9 Hz); 7.02 (d, 1H, J = 16 Hz); 6.95-7.12 (m, 3H); 7.26 (m, 1H); 7.30 (d, 1H, J = 16 Hz); 7.61 (d, 1H, J = 8.9 Hz).

Example 8. 1-[4-Methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(3,4,5-trimethoxy-phenyl)-propen-1-one
(see accompanying formula drawing VIB 123).

A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-methylallyloxy-8-acetylcoumarin (2.04 g, 0.0075 mol) and 3,4,5-trimethoxybenzaldehyde (1.47 g, 0.0075 mol) in ethanol 95%; the addition is performed

under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified. The precipitate is separated by filtration and dried under vacuum. The compound is crystallized by methanol to give 1.7 g of product m.p. 128-130°C, ¹H-NMR (CDCl₃) δ: 1.74 (s, 3H); 2.43 (s, 3H); 3.75- 3.88 (m, 9H); 4.55 (s, 2H); 4.98 (d, 2H, J = 15 Hz); 6.16 (s, 1H); 6.72 (s, 1H); 6.93 (d, 1H, J = 8.9 Hz); 6.94 (d, 1H, J = 16 Hz); 7.23(d, 1H, J = 16 Hz); 7.61 (d, 1H, J = 8.9 Hz).

Example 9. 1-[4-Methyl-7-(allyloxy)coumarin-8-yl]-3-phenyl-propen-1-one (see accompanying formula drawing VIB 158)

A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-allyloxy-8-acetylcoumarin (1.93 g, 0.0075 mol) and benzaldehyde (0.8 g, 0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified. The precipitate is separated by filtration and dried under vacuum. The compound is crystallized by methanol to give 1.1 g of product m.p. 136-139°C, ¹H-NMR (CDCl₃) δ: 2.43 (s, 3H); 4.65 (d, 2H, J = 5.1 Hz); 4.25-4.55 (m, 2H); 5.15- 5.35 (m, 1H); 6.16 (s, 1H); 6.93 (d, 1H, J = 8.9 Hz); 7.03 (d, 1H, J = 16 Hz); 7.04 - 7.15 (m, 3H); 7.15 - 7.26 (m, 2H); 7.33 (d, 1H, J = 16 Hz); 7.64 (d, 1H, J = 8.9Hz).

Example 10. 1-[4-Methyl-7-(allyloxy)coumarin-8-yl]-3-(pyridin-3-yl)-propen-1-one. (see accompanying formula drawing VIB 161).

A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-allyloxy-8-acetylcoumarin (1.93 g, 0.0075 mol) and pyridin-3-carboxyaldehyde (0.8 g, 0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified. The precipitate is separated by filtration and dried under vacuum. The compound is crystallized by ethanol to give 0.6 g of product m.p. 124-126°C, ¹H-NMR (CDCl₃) δ: 2.43 (s, 3H); 4.65 (d, 2H, J = 5.1 Hz); 4.25-

4.55 (m, 2H); 5.15 - 5.35 (m, 1H); 6.16 (s, 1H); 6.93 (d, 1H, J = 8.9 Hz); 7.08 (d, 1H, J = 16 Hz); 7.30 (d, 1H, J = 16 Hz); 7.49 (d, 1H, J = 8.9 Hz); 7.83-7.87 (m, 1H); 8.58 (d, 1H, J = 5 Hz); 6.87 (s, 1H).

5 **Example 11. 1 - [4-Methyl-7-(allyloxy)coumarin-8-yl] -3-(3-methoxyphenyl)-propen-1-one (see accompanying formula drawing VIB 159).**

10 A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-allyloxy-8-acetylcoumarin (1.93 g, 0.0075 mol) and 3-methoxybenzaldehyde (1.01 g, 0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified. The precipitate is separated by filtration and dried under vacuum. The compound is crystallized by methanol to give 1.6 g of product m.p. 61-63°C ¹H-NMR (CDCl₃) δ: 2.43 (s, 3H); 3.82 (s, 3H); 4.65 (d, 2H, J = 5.1 Hz); 5.20-5.42 (m, 2H); 5.82-6.02 (m, 1H); 6.16 (s, 1H); 6.90 (d, 1H, J = 8.9 Hz); 7.15 (d, 1H, J = 16 Hz); 6.90-7.15 (m, 3H); 7.15 (d, 1H, J = 16 Hz); 7.20-7.29 (m, 1H); 7.30 (d, 1H, J = 16 Hz); 7.64 (d, 1H, J = 8.9 Hz).

15 **Example 12. 1-[4-Methyl-7-(allyloxy)coumarin-3-yl]-3-(3,4,5-trimethoxyphenyl)-propen-1-one (see accompanying formula drawing VIB 160).**

20 A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-allyloxy-8-acetylcoumarin (1.93 g, 0.0075 mol) and 3-methoxybenzaldehyde (1.47 g, 0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified. The precipitate is separated by filtration and dried under vacuum. The compound is crystallized by methanol to give 1.8 g of product m.p. 138-140°C ¹H-NMR (CDCl₃) δ: 2.43 (s, 3H); 3.82 -3.91 (m, 9H); 4.65 (d, 2H, J = 5.1 Hz); 5.25 - 5.40 (m, 2H); 5.90 - 6.02 (m, 1H); 6.16 (s, 1H); 6.74 (s, 2H); 6.90-7.15 (m, 3H); 7.15 (d, 1H, J = 16 Hz); 7.20 - 7.29 (d, 1H, J = 16 Hz); 7.70(d, 1H, J = 8.9).

Example 13. 1-[4-Methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(3,4,5-trimethoxy-phenyl)-propen-1-one (see accompanying formula drawing VIB 126).

A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-prop-2-ynyloxy-8-acetylcoumarin (1.92 g, 0.0075 mol) and 3,4,5-trimethoxy-benzaldehyde (1.47 g, 0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified. The precipitate is separated by filtration and dried under vacuum. The compound is crystallized by ethanol to give 1.1 g of product m.p. 191-93°C, ¹H-NMR (CDCl₃) δ: 2.45 (s, 3H); 2.53-2.56 (m, 1H); 3.83-3.85 (m, 9H); 4.82 (d, 2H, J = 2.2 Hz); 6.20 (s, 1H); 6.72 (s, 2H); 6.92 (d, 1H, J = 16 Hz); 7.12 (d, 1H, J = 8.9 Hz); 7.15 (d, 1H, J = 16 Hz); 7.67 (d, 1H, J = 8.9 Hz).

Example 14. 1-[4-Methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-phenylpropen-1-one (see accompanying formula drawing VIB 124).

A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-prop-2-ynyloxy-8-acetylcoumarin (1.92 g, 0.0075 mol) and benzaldehyde (0.8 g, 0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified. The precipitate is separated by filtration and dried under vacuum. The compound is crystallized by ethanol to give 0.8 g of product m.p. 140-42°C, ¹H-NMR (CDCl₃) δ: 2.45 (s, 3H); 2.53-2.56 (m, 1H); 4.82 (d, 2H, J = 2.2 Hz); 6.20 (s, 1H); 7.02 (d, 1H, J = 16 Hz); 7.13 (d, 1H, J = 8.9 Hz); 7.32 (d, 1H, J = 16 Hz); 7.35 -7.45 (m, 3H); 7.48 - 7.52 (m, 2H); 7.67 (d, 1H, J = 8.9 Hz).

Example 15. 1-[4-Methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(pyridin-3-yl)-propen-1-one (see accompanying formula drawing VIB 125).

A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-prop-2-ynyloxy-8-acetylcoumarin (1.92 g, 0.0075 mol) and pyridin-3-carboxy aldehyde (0.8 g,

0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified. The precipitate is separated by filtration and dried under vacuum. The compound is crystallized by ethanol to give 0.7 g of product m.p. 203-205°C, ¹H-NMR (CDCl₃) δ: 2.45 (s, 3H); 2.53-2.56 (m, 1H); 4.82 (d 2H, J = 2.2 Hz); 6.20 (s, 1H); 7.02 (d, 1H, J = 16 Hz); 7.13 (d, 1H, J = 8.9 Hz); 7.32 (d, 1H, J = 16 Hz); 7.28-7.35 (m, 1H); 7.69 (d, 1H, J = 8.9 Hz); 7.88 - 7.92 (m, 1H); 8.58 - 8.62 (m, 1H); 8.66 (s, 1H).

Example 16. 1-[4-Methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(3-methoxyphenyl)-propen-1-one (see accompanying formula drawing VIB 163).

A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-prop-2-ynyloxy-8-acetylcoumarin (1.92 g, 0.0075 mol) and 3-methoxybenzaldehyde (1.01 g, 0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified. The precipitate is separated by filtration and dried under vacuum. The compound is crystallized by methanol to give 1.5 g of product m.p. 154-56°C, ¹H-NMR (CDCl₃) δ: 2.45 (s, 3H); 3.48 (m, 1H); 3.81 (s, 3H); 4.82 (d, 2H, J = 2.2 Hz); 6.15 (s, 1H); 6.90 - 7.26 (m, 5H); 7.10 (d, 1H, J = 8.9 Hz); 7.65 (d, 1H, J = 8.9 Hz).

Example 17. 1-[4-Methyl-7-(allyloxy)coumarin-8-yl]-3-(4-chlorophenyl)-propen-1-one (see accompanying formula drawing VIB 241).

A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-allyloxy-8-acetylcoumarin (1.93 g, 0.0075 mol) and 4-chlorobenzaldehyde (1.05 g, 0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified; the precipitate is separated by filtration and dried under vacuum. The compound is crystallized by methanol to give 1.1 g of product m.p. 153-155°C, ¹H-NMR (CDCl₃) δ: 2.42 (d, J=1.2 Hz, 3H), 4.65 (m, 2H), 5.2 (m, 2H), 6.15 (m, 1H), 6.91-7.61 (m, 8H).

Example 18. 1-[4-Methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(4-fluoro-phenyl)-propen-1-one (see accompanying formula drawing VIB 240).

A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-prop-2-ynyloxy-8-acetylcoumarin (1.92 g, 0.0075 mol) and 4-fluorobenzaldehyde (0.93 g, 0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified; the precipitate is separated by filtration and dried under vacuum. The compound is crystallized by ethanol to give 1.2 g of product m.p. 185-186°C, ¹H-NMR (CDCl₃) δ: 2.43 (d, J=1.2 Hz, 3H), 2.52 (m, 1H), 4.79 (d, J=1.2 Hz, 2H), 6.17 (d, J=1.2 Hz, 1H), 6.96-7.66 (m, 8H).

Example 19. 1-[3-methyl-7-methoxy)coumarin-8-yl]-3-(2-thienyl)-propen-1-one (see accompanying formula drawing VIB 242).

A solution of KOH 50% (3 ml) is added to an equimolar solution of 7-methoxy-8-acetyl-3-methylcoumarine (1.74 g, 0.0075 mol) and 2-thio-phenecarboxyaldehyde (0.84 g, 0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified; the precipitate is separated by filtration and dried under vacuum. The compound is crystallized by methanol to give 1.8 g of product m.p. 172-173°C, ¹H-NMR (CDCl₃) δ: 2.46 (d, 3H), 4.0 (s, 3H), 6.21 (d, J=1.2 Hz, 1H), 6.91-7.84 (m, 7H).

Example 20. 1-[4-Methyl-7-(allyloxy)coumarin-8-yl]-3-(2,6-dichloro-phenyl)-propen-1-one (see accompanying formula drawing VIB 243).

A solution of KOH 50% (3 ml) is added to an equimolar solution of 4-methyl-7-allyloxy-8-acetylcoumarin (1.93 g, 0.0075 mol) and 2,6-dichlorobenzaldehyde (1.31 g, 0.0075 mol) in ethanol 95%; the addition is performed under energetic stirring at room temperature. The reaction is left under stirring for one night and then diluted with water and acidified; the precipitate is separated by filtration and dried under vacuum. The compound is crystallized by methanol to give 1.1 g of product m.p. 149-151°C, ¹H-NMR (CDCl₃) δ: 2.41 (m, 3H), 4.66 (m, 2H), 5.3 (m, 2H), 5.9 (m, 1H), 6.9-7.64 (m, 8H).

BIOLOGICAL EVALUATION

Compounds VIB 106 and VIB 122 were tested for their cytotoxicity against drug-resistant cancer cells, both alone, and in combination with paclitaxel. The results of these studies are shown below.

When tested alone, compounds VIB 106 and VIB 122 were found to possess relatively low cytotoxicity ($IC_{50} > 1 \mu M$) against drug-resistant cancer cells.

The compounds were then evaluated in combination with paclitaxel for their cytostatic activity against the drug-resistant breast cancer cells MDA-435/LCC6-MDR. In the experiments, the compounds were used in combination with paclitaxel, the paclitaxel being at a concentration of $0.1 \mu M$, the IC_{50} of paclitaxel decreases by 3-5 fold when used in combination with each of compounds VIB 106 and VIB 122, i.e. from 426 nM to 130-86 nM compared with paclitaxel alone. Consequently, in the presence of these compounds, paclitaxel can recover its excellent inhibitory activities against the drug-resistant cancer cells.

Compound	IC_{50}/nM	% Reduction in IC_{50} of paclitaxel
Paclitaxel	426	-
VIB 106 + Paclitaxel	86	80
VIB 122 + Paclitaxel	130	70


Table 1

Experimental


The treatment consisted of concurrent exposure of MDA-435/LCC-MDR cells to paclitaxel in the presence or absence of the compounds reversing agent ($1 \mu M$) for 72 h *in vitro*. Assessment of cytotoxicity, i.e. cell growth inhibition, was determined according to the methods of Skehan, et al. as discussed in J. Nat. Cancer Inst., 82, 1107, 1990.

-17-


Briefly, cells were plated between 400 and 1200 cells/well in 96 well plates and incubated at 37°C for 15-18 h prior to drug addition to allow attachment of cells. Compounds were solubilized in 100% DMSO and further diluted in RPMI-1640 containing 10 mM HEPES. After a 72 h incubation, 100 μ l of ice-cold 50% TCA was added to each well and incubated for 1 h at 4°C. Plates were then washed 5 times with tap water to remove TCA, low-molecular weight metabolites and serum proteins. Sulforhodamine B (SRB) (0.4%, 50 μ l) was added to each well. Following a five minute incubation at room temperature, plates were rinsed 5 times with 0.1% acetic acid and air dried. Bound dye was solubilized with 10 mM Tris Base (pH 10.5) for 5 min on a gyratory shaker. Optical density was measured at 570 nm.




VIB 106




VIB 119




VIB 120




VIB 122




VIB 121




VIB 162




VIB 123




VIB 158




VIB 159




VIB 160




VIB 161




VIB 126




VIB 124




VIB 125




VIB 163




VIB 240



VIB 241




VIB 242



VIB 243

CLAIMS

1. A compound of Formula (I):



or a pharmaceutically acceptable salt or solvate thereof wherein:

Ar represents:

a substituted or unsubstituted, (preferably aromatic), carbocyclic or heterocyclic group, said carbocyclic or heterocyclic group containing from 5 to 10 ring atoms, said ring atoms forming one or two rings, wherein the or each ring contains 5 or 6 ring atoms, any heteroatoms being selected from N, O and S, any substituents on the Ar group being independently selected from the group consisting of:

(a) Cl, (b) Br, (c) F, (d) OH, (e) NO₂, (f) CF₃, (g) C₁₋₄ lower alkyl (in particular CH₃), (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁸) wherein R⁶ and R⁸ are the same or different and each represents H or lower C₁₋₄ alkyl, (k) OR¹⁰ wherein R¹⁰ represents a saturated or unsaturated lower C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from:

Cl, Br, F, OMe, NO₂ and CF₃,

and (l) -OCOR¹¹, wherein R¹¹ represents a saturated or unsaturated lower C₁₋₆ straight or branched hydrocarbyl group or a phenyl group;

R represents

OH, OR¹⁰ or OCOR¹¹, wherein R¹⁰ and R¹¹ are as defined above; and

-22-

R^1 represents H or a lower C_{1-6} straight or branched hydrocarbonyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from Cl, Br, F, OMe, NO_2 and CF_3 ,

with the proviso that:

- (1) when $R^1 = CH_3$ and $R = OH$:
the group Ar cannot be: 3-pyridyl, 4-pyridyl, 4-methylphenyl, 3-nitrophenyl, 3-methoxy-4-ethoxyphenyl, 3-methoxy-4-*n*-butoxyphenyl, 4-(*N,N*-dimethylamino)phenyl, 2-hydroxy-3,5-dibromophenyl, 2-hydroxy-5-methylphenyl, 4-chlorophenyl, phenyl, 3-methoxyphenyl, 4-methoxyphenyl, or 3,4-dimethoxyphenyl;
- (2) when $R^1 = CH_3$ and $R = OCOCH_3$:
the group Ar cannot be: phenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 4-(*N,N*-dimethylamino)phenyl, 3-methoxy-4-acetoxyphenyl, 3,4,5-trimethoxyphenyl, 2-chlorophenyl, or 3,4-methylenedioxyphenyl;
- (3) when $R^1 = H$ and $R = OCH_3$ or OH , the group Ar cannot be 4-methoxyphenyl; and
- (4) when $R^1 = CH_3$ and $R = OCH_3$ or OH , the group Ar cannot be 4-methoxyphenyl or 3,4-dimethoxyphenyl.

2. A compound according to Claim 1 wherein Ar represents a substituted or unsubstituted (preferably aromatic), heterocyclic group said heterocyclic group containing from 5 to 10 ring atoms, said ring atoms forming one or two rings, wherein the or each ring contains 5 or 6 ring atoms, the heteroatoms being selected from N, O and S, and any substituents on the Ar group being independently selected from the group consisting of:

- (a) Cl, (b) Br, (c) F, (d) OH, (e) NO_2 , (f) CF_3 , (g) C_{1-4} lower alkyl (in particular CH_3), (h) SCH_3 , (i) $NHCOCH_3$, (j) $N(R^6)(R^6)$ wherein R^6 and R^6 are the same or different and each represents H or lower C_{1-4} alkyl, (k) OR^{10} wherein R^{10} represents a saturated or unsaturated lower C_{1-6} straight or branched hydrocarbonyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from:

Cl, Br, F, OMe, NO₂ and CF₃,

and (l) -OCOR¹¹, wherein R¹¹ represents a saturated or unsaturated lower C₁₋₆ straight or branched hydrocarbyl group or a phenyl group.

3. A compound according to any preceding claim wherein the Ar group is a substituted or unsubstituted (preferably aromatic), heterocyclic group, said heterocyclic group containing from 5 to 10 ring atoms, wherein at least one of the ring atoms is a nitrogen atom and any substituent on the ring is as defined as for Claim 1.

4. A compound according to any preceding claim wherein Ar represents pyridyl or indolyl.

5. A compound according to Claim 1 wherein Ar represents a substituted or unsubstituted (preferably aromatic), carbocyclic group, said carbocyclic group containing from 5 to 10 ring atoms, said ring atoms forming one or two rings, wherein the or each ring contains 5 or 6 ring atoms, and any substituents on the Ar group being independently selected from the group consisting of:

(a) Cl, (b) Br, (c) F, (d) OH, (e) NO₂, (f) CF₃, (g) C₁₋₄ lower alkyl (in particular CH₃), (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁸) wherein R⁶ and R⁸ are the same or different and each represents H or lower C₁₋₄ alkyl, (k) OR¹⁰ wherein R¹⁰ represents a saturated or unsaturated lower C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from:

Cl, Br, F, OMe, NO₂ and CF₃,

and (l) -OCOR¹¹, wherein R¹¹ represents a saturated or unsaturated lower C₁₋₆ straight or branched hydrocarbyl group or a phenyl group.

6. A compound according to any preceding claim wherein any substituents on the Ar group are selected from the group consisting of: NHCOCH₃, N(R⁶)(R⁸), OR¹⁰ and -OCOR¹¹, wherein R⁶, R⁸, R¹⁰ and R¹¹ are as defined in Claim 1.

-24-

7. A compound according to any preceding claim wherein Ar is substituted with one or more OR^{10} groups, wherein R^{10} represents a saturated or unsaturated lower C_{1-6} straight or branched hydrocarbyl group.
8. A compound according to Claim 7 wherein R^{10} represents methyl.
9. A compound according to any of Claims 5 to 8 wherein Ar is selected from phenyl or phenyl substituted with 1, 2 or 3 methoxy groups.
10. A compound according to any preceding claim wherein R^{10} represents an unsaturated lower C_{1-6} straight or branched hydrocarbyl group.
11. A compound according to Claim 10 wherein R represents $OCH=C(CH_3)_2$, $OCH_2CMe=CH_2$, $OCH_2CH=CH_2$ or $OCH_2C\equiv CH$.
12. A compound according to Claim 1 wherein Ar is selected from phenyl, trimethoxyphenyl, 3-pyridyl, 4-pyridyl or 3-indolyl; and R is selected from $OCH=C(CH_3)_2$, $OCH_2CMe=CH_2$, $OCH_2CH=CH_2$ or $OCH_2C\equiv CH$.
13. A compound according to any preceding claim wherein R^1 represents a lower C_{1-6} straight or branched hydrocarbyl group.
14. A compound according to Claim 13 wherein R^1 represents methyl.
15. A compound according to Claim 3 wherein:
Ar represents
phenyl, which may be unsubstituted or substituted by one, two or three substituents independently selected from
Cl, Br, F, OMe, NO_2 , CF_3 , C_{1-4} lower alkyl (in particular CH_3), NMe_2 , NEt_2 , SCH_3 and $NHCOCH_3$;

-25-

thienyl, 2-furyl, 3-pyridyl, 4-pyridyl or indolyl.

R represents

OH or OCH_2R^1 , wherein R^1 is selected from $-\text{CH}=\text{CMe}_2$, $-\text{CMe}=\text{CH}_2$, $-\text{CH}=\text{CH}_2$ and $-\text{C}=\text{CH}$.

16. A compound according to any preceding claim wherein R^6 and R^8 are the same or different and each represents H or lower C_{1-4} alkyl.

17. A compound according to any preceding claim wherein R^{10} and R^{11} represents a saturated or unsaturated C_{1-6} straight chain or branched hydrocarbyl group.

18. A compound according to any Claim 17 wherein R^{10} and R^{11} are selected from methyl, ethyl, n-propyl or isopropyl.

19. A compound of Formula (I) according to Claim 1 selected from the following:

1-[4-Methyl-7-(2-methylprop-1-enyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one
(VIB 106),

1-[4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl]-3-phenylpropen-1-one
(VIB 119),

1-[4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl]-3-(3,4,5-trimethoxyphenyl)-
propen-1-one (VIB 120),

1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one
VIB 122),

1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-phenylpropen-1-one (VIB 121),

1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(3-methoxyphenyl)propen-1-one
(VIB 162),

1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(3,4,5-trimethoxyphenyl)propen-
1-one (VIB 123),


1-[4-methyl-7-(allyloxy)coumarin-8-yl]-3-phenylpropen-1-one (VIB 158),

1-[4-methyl-7-(allyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one (VIB 161),

- 1-[4-methyl-7-(allyloxy)coumarin-8-yl]-3-(3-methoxyphenyl)propen-1-one
(VIB 159),
1-[4-methyl-7-(allyloxy)coumarin-3-yl]-3-(3,4,5-trimethoxyphenyl)propen-1-one
(VIB 160),
1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(3,4,5-trimethoxyphenyl)propen-1-one
(VIB 126),
1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-phenylpropen-1-one (VIB 124),
1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(pyridin-3-yl)propen-1-one
(VIB 125), and
1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(3-methoxyphenyl)propen-1-one
(VIB 163).

20. A compound of Formula (I) as defined in any preceding claim for use as a antiproliferative medicament.

21. Use of a compound of Formula (I):



or a pharmaceutically acceptable salt or solvate thereof wherein:

Ar represents:

a substituted or unsubstituted, (preferably aromatic), carbocyclic or heterocyclic group, said carbocyclic or heterocyclic group containing from 5 to 10 ring atoms, said ring atoms forming one or two rings, wherein the or each ring contains 5 or 6 ring atoms, any heteroatoms being selected from

N, O and S, any substituents on the Ar group being independently selected from the group consisting of:

(a) Cl, (b) Br, (c) F, (d) OH, (e) NO₂, (f) CF₃, (g) C₁₋₄ lower alkyl (in particular CH₃), (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁸) wherein R⁶ and R⁸ are the same or different and each represents H or lower C₁₋₄ alkyl, (k) OR¹⁰ wherein R¹⁰ represents a saturated or unsaturated lower C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from:

Cl, Br, F, OMe, NO₂ and CF₃,

and (l) -OCOR¹¹, wherein R¹¹ represents a saturated or unsaturated lower C₁₋₆ straight or branched hydrocarbyl group or a phenyl group;

R represents

OH, OR¹⁰ or OCOR¹¹, wherein R¹⁰ and R¹¹ are as defined above; and

R¹ represents H or a lower C₁₋₆ straight or branched hydrocarbyl group which may be unsubstituted or substituted by 1, 2 or 3 substituents selected from Cl, Br, F, OMe, NO₂ and CF₃,

in the manufacture of a medicament for the treatment or prevention of neoplasms.

22. Use according to Claim 21 wherein the compound of Formula (I) is as defined in any of Claim 1 to 19.

23. Use according to Claim 21 or 22 wherein the neoplasms are located in the uterus, ovary or breast.

24. Use according to any of Claims 21 to 23 in the manufacture of a medicament for the treatment of paclitaxel- and docetaxel-resistant cancer cells.

25. Use according to any of Claims 21 to 24 in the manufacture of an antiproliferative medicament for combination therapy.

-28-

26. Use according to Claim 25 in the manufacture of an antiproliferative medicament in combination with one or more antineoplastic agents.

27. Use according to Claim 26 wherein the antineoplastic agent comprises paclitaxel or docetaxel.

28. Use of a compound of Formula (I) as defined in Claim 21 for the manufacture of a medicament for the treatment or prevention of menopausal disorders and osteoporosis.

29. A pharmaceutical composition comprising one or more of the compounds of Formula (I) as defined in any of Claims 1 to 19, in combination with one or more pharmaceutically acceptable excipients.

30. A pharmaceutical composition according to Claim 29 further comprising one or more antineoplastic agents.

31. A pharmaceutical composition according to Claim 30 wherein the antineoplastic agent is selected from paclitaxel or docetaxel.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/08367

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D311/18 C07D405/06 C07D409/06 A61K31/37 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR 2 387 956 A (UNICLER) 17 November 1978 (1978-11-17)	1-18
A	table I, compound D199 the whole document	20-30
X	KHAN, M. S. Y. ET AL: "Synthesis of new.alpha.-pyronoflavones and related products. Part II" INDIAN J. CHEM., SECT. B (1993), 32B(8), 817-21, XP000981909 the whole document	1-18
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

7 February 2001

Date of mailing of the international search report

21/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Beslier, L

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/08367

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SHARAN, P. ET AL: "Synthesis of some 7-hydroxy-4-methylcoumarin-8-yl chalcones and related isoxazoles as potential fungicides" J. INDIAN CHEM. SOC. (1989), 66(6), 393-4, XP000979582 the whole document ---	1-18
X	SANGWAN, NARESH K. ET AL: "Synthesis and biological properties of substituted 2H-1-benzopyran-2-ones and 2H,10H-benzo[1,2-b:3,4-b']dipyrans-2,10-diones" J. PRAKT. CHEM. (1988), 330(1), 137-41 , XP000979579 the whole document ---	1-18
X	AHLUWALIA, V. K. ET AL: "New route to synthesis of some 8-(dihydrocinnamoyl)dihydrocoumarin derivatives" INDIAN J. CHEM., SECT. B (1988), 27B(1), 70-1, XP000979595 the whole document ---	1-18
A	WO 96 19209 A (INDENA S.P.A.) 27 June 1996 (1996-06-27) cited in the application the whole document ---	1,20-30
A	WO 91 17749 A (BAYLOR COLLEGE OF MEDICINE) 28 November 1991 (1991-11-28) cited in the application the whole document ---	1,20-30
A	WO 96 22985 A (WARNER-LAMBERT CO.) 1 August 1996 (1996-08-01) the whole document ---	1,20-30
A	WO 95 18803 A (ALLERGAN, INC.) 13 July 1995 (1995-07-13) the whole document -----	1,20-30

- 1 MAR 2004

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 00/08367

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2387956 A	17-11-1978	NONE	
WO 9619209 A	27-06-1996	IT MI942568 A	20-06-1996
		AU 689357 B	26-03-1998
		AU 4301996 A	10-07-1996
		CA 2208351 A	27-06-1996
		CN 1170362 A	14-01-1998
		CZ 9701869 A	12-11-1997
		EP 0800387 A	15-10-1997
		FI 972641 A	14-08-1997
		HU 77438 A	28-04-1998
		JP 10511346 T	04-11-1998
		NO 972842 A	19-06-1997
		PL 320787 A	27-10-1997
		SI 9520139 A, B	31-10-1997
		SK 78197 A	10-12-1997
		US 5808137 A	15-09-1998
WO 9117749 A	28-11-1991	AU 7963691 A	10-12-1991
		CA 2084208 A	18-11-1991
		EP 0528975 A	03-03-1993
		JP 5509078 T	16-12-1993
WO 9622985 A	01-08-1996	US 5525625 A	11-06-1996
		AT 181913 T	15-07-1999
		AU 690400 B	23-04-1998
		AU 4245696 A	14-08-1996
		CA 2208075 A	01-08-1996
		DE 69510696 D	12-08-1999
		DE 69510696 T	23-12-1999
		DK 805807 T	17-01-2000
		EP 0805807 A	12-11-1997
		ES 2137554 T	16-12-1999
		GR 3031295 T	31-12-1999
		JP 10512878 T	08-12-1998
		NZ 297320 A	28-05-1999
		ZA 9600528 A	15-08-1996
WO 9518803 A	13-07-1995	US 5399561 A	21-03-1995
		AU 684613 B	18-12-1997
		AU 1725695 A	01-08-1995
		CA 2180360 A	13-07-1995
		EP 0738267 A	23-10-1996
		JP 9508104 T	19-08-1997